MoleProLink-RL: geometric transport for domain-policy reinforcement learning in drug-target interaction prediction
Accurate drug-target interaction (DTI) prediction is vital to modern discovery workflows, yet models trained in one setting often underperform when chemotypes, protein families, or assay conditions shift. MoleProLink-RL addresses this challenge as a model-first solution that couples chemically faithful representations with geometry-aware alignment and stability-aware decision making. The system combines graph-transformer drug encoders and residual protein embeddings with an unsupervised distribution alignment layer that respects molecular similarity through a DTI-aware transport distance complemented by kernel mean embeddings, while a lightweight reinforcement-learning objective regulates ranking stability across latent sub-environments under a small trust region to a supervised reference. Unlike pipelines that bolt adaptation onto frozen features or tune policies post hoc, MoleProLink-RL trains representation, alignment, and decisions end-to-end so that what the model learns to represent directly improves how it prioritizes candidates under shift. We provide a Fisher-Wasserstein view that clarifies why joint updates are safe in parameter space and effective on distribution space, and we validate the approach on Human, C. elegans, and Davis benchmarks with realistic class imbalance, comprehensive ablations, and diagnostics for calibration and interpretability. The result is a practical, data-efficient DTI model that maintains top-of-list precision when conditions change, narrowing the gap between benchmark performance and laboratory impact.
Authors
- Dong Zhu (ORCID: https://orcid.org/0000-0002-6700-2743)
- Liang Wu (ORCID: https://orcid.org/0000-0002-9988-8593)
- Mingchen Xie (ORCID: https://orcid.org/0000-0002-4109-933X)
- Ruhan Wang (ORCID: https://orcid.org/0000-0001-5874-4350)
- Bibo Wang (ORCID: https://orcid.org/0000-0003-0552-2548)
- J. F. Sun (ORCID: https://orcid.org/0009-0002-8267-7180)
- Chao Zhang (ORCID: https://orcid.org/0000-0002-0568-9922)
- Xu Li (ORCID: https://orcid.org/0000-0003-2772-7114)
- Haitao Wu (ORCID: https://orcid.org/0000-0002-8439-382X)
- Changwei Zheng (ORCID: https://orcid.org/0000-0003-4443-6044)
- Donghao Xu (ORCID: https://orcid.org/0000-0003-0568-8740)
Institutions
- Qingdao University (CN)
- Jinan University (CN)
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Ruijin Hospital (CN)
- Shanghai Cancer Institute (CN)
- Affiliated Hospital of Qingdao University (CN)
- Zhongshan Hospital (CN)
- Shanghai First People's Hospital (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- npj Digital Medicine
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1038/s41746-025-02158-0
- Citations
- 1
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.50